However, even in large real world cohorts of patients with T1D on GLP-1RA, low rates of hypoglycemia were observed ( ADJUNCT ONE and TWO trials, the 2 largest studies with GLP-1RA in T1D, reported increased rates of hypoglycemia
J Clin Oncol 2002;20:2575-601
Lastly, a comparison of semaglutide-induced weight loss versus diet-induced proteomic changes would be highly valuable for this study
Tirzepatide was approved by the FDA to treat type 2 diabetes in 2022 and obesity in 2023 and has since become a blockbuster drug, particularly for treatment of obesity
If youre new to tirzepatide or looking for additional resources, be sure to explore Zappy Health for more tips and expert advice on managing diabetes and optimizing your treatment.
Request supervised injection training from your healthcare provider if uncertain about technique